Table 2.

Frequency of motor seizures and of all countable seizures at baseline and at 3, 6, and 12 months of cannabidiol treatment in whole cohort, pediatric, and adult cohort.

Seizure types and cohort	Visit	N	Median	Range	p
Motor seizures
All patients	Baseline	32	21.8	1.7–330
	3 months	32	8.5	0–225	<0.001
	6 months	25	7.0	0–124.7	<0.001
	12 months	15	8.5	0–89.5	=0.008
Adults	Baseline	14	10.2	1.7–53.0
	3 months	14	7.0	0.8–33.0	<0.001
	6 months	7	3.4	0.3–14.0	=0.06
	12 months	3	3.0	0–12.0	=0.05
Children	Baseline	18	42.0	1.7–330
	3 months	18	13.0	0–225	<0.001
	6 months	18	11.7	0–224.7	<0.001
	12 months	12	7.5	0–89.0	=0.005
All countable seizures
All patients	Baseline	32	21.3	1.7–330
	3 months	32	11.9	1–225	<0.001
	6 months	25	11.7	0.7–124.7	<0.001
	12 months	15	7.5	0.5–89.0	=0.008
Adults	Baseline	14	12.2	2.7–53.0
	3 months	14	7.2	1.0–33.0	=0.016
	6 months	7	15.0	2.0–28.7	=0.31
	12 months	3	3.0	0.7–18	=0.25
Children	Baseline	18	42.0	1.7–330
	3 months	18	14.7	1.0–225.0	<0.001
	6 months	18	11.7	0.7–124.7	=0.005
	12 months	12	10	0.5–89.0	=0.001

Significance level of seizure frequency at each visit compared to baseline.